AIMEI HEALTH TECHNOLOGY CO., LTD RECEIVES NASDAQ NOTICE REGARDING DELAYED QUARTERLY REPORT

Aimei Health Technology (Nasdaq: AFJK) received a Nasdaq notice on May 19, 2026, due to a delayed Form 10-Q for the quarter ended March 31, 2026, missing the May 15 deadline.

Rhea-AI Summary

Aimei Health Technology (Nasdaq: AFJK) received a Nasdaq notice on May 19, 2026, due to a delayed Form 10-Q for the quarter ended March 31, 2026, missing the May 15 deadline.

The notice has no immediate listing impact, but prolonged non-compliance could lead to Nasdaq delisting if the report is not filed or a compliance plan is not accepted.

Positive

• Nasdaq notice has no immediate effect on AFJK listing or trading
• Company has 60 days to file Form 10-Q or submit compliance plan
• Potential extension up to 180 days from due date if plan accepted
• Company working diligently and expects to regain listing rule compliance

Negative

• AFJK currently not in compliance with Nasdaq Listing Rule 5250(c)(1)
• Risk of Nasdaq delisting if compliance not timely regained
• Possible Nasdaq hearings panel process if compliance plan is not accepted

Argus May 21 session

-3.97% close to close Open Argus

Details

News Market Reaction – AFJK

In the May 21 session, AFJK declined 3.97%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights that Aimei Health Technology failed to file its Form 10-Q for the quart...

Analysis

This announcement highlights that Aimei Health Technology failed to file its Form 10-Q for the quarter ended March 31, 2026 by the May 15, 2026 deadline and received a Nasdaq deficiency notice under Rule 5250(c)(1). The company has 60 days to file or submit a compliance plan, and up to 180 days to regain compliance if a plan is accepted. Investors may watch for the actual 10-Q filing and any further Nasdaq correspondence.

Key Figures

10-Q period end: March 31, 2026 10-Q due date: May 15, 2026 Nasdaq notice date: May 19, 2026 +2 more

10-Q period end

March 31, 2026

Quarterly Report on Form 10-Q period end

10-Q due date

May 15, 2026

SEC filing deadline for Quarterly Report

Nasdaq notice date

May 19, 2026

Date of Nasdaq Listing Qualifications Notice

Initial cure period

60 calendar days

Time to file 10-Q or submit compliance plan

Max compliance window

180 calendar days

Potential maximum period from due date to regain compliance

Historical Context

1 past event · Latest: Apr 21

1 event

1. Apr 21

   Nasdaq non-compliance

   24h Move

   +1.4%

   Nasdaq notice for delayed Form 10-K and cure-period outline.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

form 10-q, nasdaq listing rule 5250(c)(1), u.s. securities and exchange commission, deficiency notification

4 terms

form 10-q regulatory

"its Quarterly Report on Form 10-Q for the period ended March 31, 2026"

A Form 10-Q is a detailed report that publicly traded companies are required to file with regulators three times a year, providing an update on their financial health and business activities. It is important for investors because it offers timely insights into a company's performance, helping them make informed decisions about buying or selling stocks. Think of it as a regular check-up report that shows how well a company is doing.

nasdaq listing rule 5250(c)(1) regulatory

"not in compliance with the requirements for continued listing under Nasdaq Listing Rule 5250(c)(1)"

Nasdaq Listing Rule 5250(c)(1) requires companies listed on the Nasdaq stock exchange to promptly notify the exchange if their stock price falls below a certain minimum level, known as the "initial listing standards." This rule helps ensure that investors are aware of significant declines in a company's stock value, which could signal financial trouble or increased risk. Essentially, it helps maintain transparency and protect investors by keeping them informed about important changes in a company's stock performance.

u.s. securities and exchange commission regulatory

"filing its Quarterly Report on Form 10-Q ... with the U.S. Securities and Exchange Commission"

The U.S. Securities and Exchange Commission is a government agency responsible for overseeing the stock market and protecting investors. It sets rules to ensure that companies share truthful information and that trading is fair, helping to maintain trust in the financial system. This oversight is important because it helps prevent fraud and ensures that investors can make informed decisions.

deficiency notification regulatory

"requires prompt disclosure of receipt of a deficiency notification"

A deficiency notification is a formal notice from a regulator, exchange, or reviewer pointing out missing, unclear, or inadequate information in a company’s filing or application. It matters to investors because it can delay approvals, listings, fundraising or product launches and signal compliance or disclosure problems; think of it as a teacher returning a homework sheet with items circled that must be fixed before the work is accepted.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

New York, NY, May 20, 2026 (GLOBE NEWSWIRE) -- Aimei Health Technology Co., Ltd (the “Company”) (Nasdaq: AFJK) today announced that on May 19, 2026, it received a notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as a result of the Company’s delay in filing its Quarterly Report on Form 10-Q for the period ended March 31, 2026 (the “Quarterly Report”) with the U.S. Securities and Exchange Commission (the “SEC”), the Company is not in compliance with the requirements for continued listing under Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”). The Quarterly Report was due on May 15, 2026.

The Notice has no immediate effect on the listing or trading of the Company’s securities on Nasdaq. However, if the Company fails to timely regain compliance with the Listing Rule, the Company’s securities will be subject to delisting from Nasdaq.

Under Nasdaq rules, the Company has 60 calendar days from the date of the Notice to either file the Quarterly Report or submit a plan to Nasdaq to regain compliance with Nasdaq’s listing rules. If a plan is submitted and accepted, the Company may be granted up to 180 calendar days from the Quarterly Report’s due date to regain compliance. If Nasdaq does not accept the Company’s plan, the Company will have the opportunity to appeal that decision to a Nasdaq hearings panel.

The Company is working diligently to complete and file the Quarterly Report and expects to regain compliance with the Listing Rule.

This announcement is made in compliance with Nasdaq Listing Rule 5810(b), which requires prompt disclosure of receipt of a deficiency notification.

About Aimei Health Technology Co., Ltd

Aimei Health Technology Co., Ltd is a blank check company incorporated as a Cayman Islands exempted company with limited liability for the purpose of entering into a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities. The Company’s efforts to identify a prospective target business will not be limited to a particular industry or geographic region, although the Company intends to pursue prospective targets focused on healthcare innovation.

Forward-Looking Statements

This press release contains “forward-looking” statements within the meaning of the federal securities laws. These statements are based on management’s current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied. The Company undertakes no obligation to update any forward-looking statements except as required by applicable law.

For investor and media inquiries, please contact:

Aimei Health Technology Co., Ltd
10 East 53rd Street, Suite 3001
New York, NY 10022
Attention: Junheng Xie
Email: Xiejunheng@aimeihealth.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Why did Aimei Health Technology (AFJK) receive a Nasdaq notice on May 19, 2026?

Aimei Health Technology received the Nasdaq notice because it delayed filing its Form 10-Q for the quarter ended March 31, 2026. According to the company, this delay means it is not compliant with Nasdaq Listing Rule 5250(c)(1) governing timely periodic SEC filings.

Does the Nasdaq deficiency notice affect the current trading of AFJK stock?

The Nasdaq notice has no immediate effect on the listing or trading of AFJK shares. According to the company, its securities will remain on Nasdaq while it works to file the delayed Form 10-Q and regain compliance within the allowed timeframe.

How long does Aimei Health Technology (AFJK) have to regain Nasdaq compliance?

Aimei Health Technology has 60 calendar days from the May 19, 2026 notice to file the Form 10-Q or submit a compliance plan. According to the company, if Nasdaq accepts the plan, it may have up to 180 days from the report’s due date.

What happens to AFJK if Nasdaq does not accept its compliance plan?

If Nasdaq does not accept the company’s plan, Aimei Health Technology can appeal to a Nasdaq hearings panel. According to the company, failure to regain compliance in time would make its securities subject to potential delisting from the Nasdaq Capital Market.

What is Aimei Health Technology (AFJK) doing about its delayed Form 10-Q?

Aimei Health Technology states it is working diligently to complete and file the delayed Form 10-Q. According to the company, it expects to regain compliance with Nasdaq Listing Rule 5250(c)(1) within the permitted period following the deficiency notice received on May 19, 2026.

What listing rules apply to AFJK after the delayed quarterly report notice?

AFJK is currently out of compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely SEC filings. According to the company, this notice was disclosed under Listing Rule 5810(b), mandating prompt public disclosure of deficiency notifications to investors and the market.